Dopamine receptor agonists in current clinical use: Comparative dopamine receptor binding profiles defined in the human striatum

Journal of Neural Transmission

Volumn 110, Issue 10, 2003, Pages 1119-1127

  Gerlach, M ^a   Double, K ^b,c   Arzberger, T ^b   Leblhuber, F ^d   Tatschner, T ^b   Riederer, P ^b  

^a Clinical Neurochemistry   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

Dopamine D 2 agonist; Dopamine D1 agonist; Dopamine D3 agonist; Dopamine receptor agonists; Dopamine receptors; Parkinson therapy; Receptor binding

Indexed keywords

CABERGOLINE; DIHYDROERGOCRYPTINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; ERGOLINE DERIVATIVE; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SND 919CL2Y;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; HYPOTHESIS; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN;

EID: 0142091254     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-003-0027-5     Document Type: Article

References (30)

1. Andersen PH, Jansen JA (1990) Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur J Pharmacol [Mol Pharmacol Sect] 188: 335-347
2. Battistin L, Bardin PG, Ferro-Milone F, Ravenna C, Toso V, Reboldi G (1999) Alpha-dihydro-ergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study. Acta Neurol Scand 99: 36-42
3. Brecht HM (1998) A comparison of dopamine agonists. Akt Neurol [Suppl 4] 25: 310-316
4. 4.4 receptors expressed in chinese hamster ovary cells. Br J Pharmacol 127: 1696-1702
5. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety 11: 58-65
6. 3 dopamine receptors in human striatum. Prog Neuropsychopharmacol Biol Psychiatry 19: 1147-1154
7. 2 agonist. Pharmcol Biochem Behav 38: 147-154
8. th November, Miami, Florida, USA (Mov Disord [Suppl 5] 17: S44, P96)
9. Gsell W, Lange KW, Pfeuffer R, Heckers S, Heinsen H, Senitz D, Jellinger K, Ransmayr G, Wichart I, Vock R, Beckmann H, Riederer P (1993) How to run a brain bank. A report from the Austro-German brain bank. J Neural Transm [Suppl] 39: 31-70
10. 2 receptor expressing neurons. Neuropsychopharmacol 20: 60-80
11. Guttman M and the International Pramipexole-Bromocriptine Study Group (1997) Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 49: 1060-1065
12. Hanna PA, Ratkos L, Ondo WG, Jankovic J (2001) Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm 108: 63-70
13. Jaber M, Robinson SW, Missale C, Caron MG (1996) Dopamine receptors and brain function. Neuropharmacol 35: 1503-1519
14. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93-96
15. 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34: 2251-2259
16. 3 receptors. Relevance for drug treatment of Parkinson's disease. CNS Drugs 12: 391-402
17. Marek K, Seibyl J, Shoulson I, Holloway R, Kieburtz K, McDermott M, Kamp C, Shinaman A, Fahn S, Lang A, Weiner W, Welsh M and the Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287: 1653-1661
18. 4receptors. Eur J Pharmacol [Mol Pharmac Sect] 290: 29-36
19. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin J-A, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptors. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303: 791-804
20. Oertel WH (2000) Pergolide vs L-dopa (PELMOPET). Mov Disord [Suppl 3] 15: M86, 4
21. Parkinson Study Group (1997) Safety and efficacy of pramipexole in early Parkinson's disease: a randomized dose-ranging study. JAMA 278: 125-138
22. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson's disease. A randomized controlled trial. JAMA 284: 1931-1938
23. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484-1491
24. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD, Dubini A and the PKDS009 Study Group (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs [Suppl 1] 55: 23-30
25. Schmauss C (2000) Dopamine receptors: novel insights from biochemical and genetic studies. The Neuroscientist 6: 127-138
26. 3) as a target for neuroleptics. Nature 34: 146-151
27. Uitti RJ, Ahlskog JE (1996) Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 5: 369-388
28. 1 receptor agonists. CNS Drugs 11: 83-91
29. Vinar O, Zapletalek M, Kazdova E, Nahunek K, Molcan J (1985) Antidepressant effects of lisuride are not different from effects of amitriptyline and nortriptyline. Activ Nerv Sup (Praha) 27: 250-251
30. Whone AL, Remy P, Davis MR, Sabolek M, Nahmias C, Stoessl J, Watts RL, Brooks DJ (2002) The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa. Neurology [Suppl 7] 58: A11.006, A82